Related Experiment Video
Updated: Jun 11, 2025

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
Published on: April 11, 2025
Identification of Gαi3 as a promising molecular oncotarget of pancreatic cancer
Jian-Zhuo Jiang1, Yin-Biao Qiao2, Xiao-Ren Zhu3
1Clinical Research and Lab Center, Affiliated Kunshan Hospital of Jiangsu University, Kunshan, China.
Abstract:
The increasing mortality rate of pancreatic cancer globally necessitates the urgent identification for novel therapeutic targets. This study investigated the expression, functions, and mechanistic insight of G protein inhibitory subunit 3 (Gαi3) in pancreatic cancer. Bioinformatics analyses reveal that Gαi3 is overexpressed in human pancreatic cancer, correlating with poor prognosis, higher tumor grade, and advanced classification. Elevated Gαi3 levels are also confirmed in human pancreatic cancer tissues and primary/immortalized cancer cells. Gαi3 shRNA or knockout (KO) significantly reduced cell viability, proliferation, cell cycle progression, and mobility in primary/immortalized pancreatic cancer cells. Conversely, Gαi3 overexpression enhanced pancreatic cancer cell growth. RNA-sequencing and bioinformatics analyses of Gαi3-depleted cells indicated Gαi3's role in modulating the Akt-mTOR and PKA-Hippo-YAP pathways. Akt-S6 phosphorylation was decreased in Gαi3-depleted cells, but was increased with Gαi3 overexpression. Additionally, Gαi3 depletion elevated PKA activity and activated the Hippo pathway kinase LATS1/2, leading to YAP/TAZ inactivation, while Gαi3 overexpression exerted the opposite effects. There is an increased binding between Gαi3 promoter and the transcription factor TCF7L2 in pancreatic cancer tissues and cells. Gαi3 expression was significantly decreased following TCF7L2 silencing, but increased with TCF7L2 overexpression. In vivo, intratumoral injection of Gαi3 shRNA-expressing adeno-associated virus significantly inhibited subcutaneous pancreatic cancer xenografts growth in nude mice. A significant growth reduction was also observed in xenografts from Gαi3 knockout pancreatic cancer cells. Akt-mTOR inactivation and increased PKA activity coupled with YAP/TAZ inactivation were also detected in xenograft tumors upon Gαi3 depletion. Furthermore, bioinformatic analysis and multiplex immunohistochemistry (mIHC) staining on pancreatic cancer tissue microarrays showed a reduced proportion of M1-type macrophages and an increase in PD-L1 positive cells in Gαi3-high pancreatic cancer tissues. Collectively, these findings highlight Gαi3's critical role in promoting pancreatic cancer cell growth, potentially through the modulation of the Akt-mTOR and PKA-Hippo-YAP pathways and its influence on the immune landscape.
Insights
G protein inhibitory subunit 3 (Gαi3) promotes pancreatic cancer growth by activating Akt-mTOR and PKA-Hippo-YAP pathways. Targeting Gαi3 inhibits tumor growth and alters the immune microenvironment, offering a potential therapeutic strategy for pancreatic cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Pancreatic cancer has a high mortality rate, necessitating new therapeutic targets.
- G protein inhibitory subunit 3 (Gαi3) is a potential target, but its role in pancreatic cancer is not fully understood.
Purpose of the Study:
- To investigate the expression, function, and mechanistic role of Gαi3 in pancreatic cancer.
- To explore Gαi3's potential as a therapeutic target for pancreatic cancer.
Main Methods:
- Bioinformatic analyses of patient data and cell lines.
- In vitro studies using Gαi3 knockdown (shRNA) or knockout (KO) cells.
- RNA-sequencing to identify modulated pathways.
- In vivo studies using xenograft mouse models.
- Multiplex immunohistochemistry (mIHC) for immune cell profiling.
Main Results:
- Gαi3 is overexpressed in pancreatic cancer, correlating with poor prognosis.
- Gαi3 depletion reduced cancer cell viability, proliferation, and mobility, while overexpression enhanced growth.
- Gαi3 modulates Akt-mTOR and PKA-Hippo-YAP pathways, influencing cell cycle and survival.
- TCF7L2 transcriptionally regulates Gαi3 expression.
- Gαi3 inhibition suppressed tumor growth in vivo and altered the tumor immune microenvironment (reduced M1 macrophages, increased PD-L1).
Conclusions:
- Gαi3 is a critical driver of pancreatic cancer progression.
- Targeting Gαi3 offers a promising therapeutic strategy by inhibiting tumor growth and modulating the immune response.
- Gαi3's role in Akt-mTOR and PKA-Hippo-YAP pathway regulation provides mechanistic insight into its oncogenic functions.
More Related Videos
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
03:42Author Spotlight: Validating Cancer Therapy Responses with Desmoplastic Spheroid Models
Published on: September 27, 2024
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...